Rosopatamab

Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency[1].

Product Specifications

CAS Number

[2260767-49-3]

Product Name Alternative

HUJ-591; TLX591

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

PSMA; Radionuclide-Drug Conjugates (RDCs)

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rosopatamab.html

Purity

99.50

Solubility

10 mM in DMSO

Smiles

[Rosopatamab]

Molecular Weight

(144.11 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Antonini P, et al. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT) [J]. 2022.|[2]Johnstone CN, et al. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025 Jan 30:jnumed.124.268695.|[3]Johnstone C, et al. Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma. 2023.